
Management of Metastatic Non-Small Cell Lung Cancer without an Actionable Mutation
Oncology Today with Dr Neil Love
00:00
Is There a KRS G12A Mutation in Melanoma?
The role of CTA-4 inhibition is someone went debated as monotherapy. In melanoma, at least historically, that was seen, we don't see the same thing in lung cancer,. So she has a KRS G12A mutation and you were kind of getting into that in your talk. Can you kind of just globally summarize that? Is it what specific KRS mutations seem to be predictive of benefit? And then what sub-mutations or additional mutations, like in what situations do you look at and go, oh, this patient's probably not going to do as well? Yeah, so obviously in the sort of new treatment landscape where we have specific inhibitors of KRS G
Transcript
Play full episode